Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange Detected- Minor metadata update: Revision: v3.4.2, and removal of a few related topics (Lung cancer; MedlinePlus Genetics; Revision: v3.4.1). Core study content, eligibility criteria, outcomes, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check20 days agoChange DetectedRevision history updated from v3.4.0 to v3.4.1. No changes to the study content or results are evident in the visible text.SummaryDifference0.0%

- Check27 days agoChange DetectedShow glossary, Lung cancer, and related topics (MedlinePlus Genetics) were added, along with updated revision information (Revision: v3.4.0). Older labels such as Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.3%

- Check34 days agoChange DetectedRemoved 'Lung cancer' and 'MedlinePlus Genetics' from the related topics section. This reduces metadata links without changing the study details or eligibility information.SummaryDifference0.1%

- Check42 days agoChange DetectedNew related topic tags for Lung cancer and MedlinePlus Genetics were added, and the page footer now shows revision 3.3.4 (replacing 3.3.3). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check56 days agoChange DetectedRemoval of related topics on the page, including Lung cancer and MedlinePlus Genetics, which are navigational aids rather than core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.